#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bronchiectasis Follicle centre lymphoma follicular grade I, II – III Postprandial hypoglycaemia Anaemia Haemophilia A without inhibitors Scleroderma associated digital ulcer Vaginal cancer Narcolepsy IPEX syndrome Retinal artery occlusion Anti-HLA antibody test positive Monogenic diabetes Thalassaemia beta Stress cardiomyopathy Short stature homeobox gene mutation More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Treatment Nodal marginal zone B-cell lymphoma Leiomyosarcoma recurrent – Treatment Bronchiolitis obliterans syndrome – Treatment Splenic marginal zone lymphoma – Trials in Disease Atypical teratoid/rhabdoid tumour of CNS – Diagnostics Arterial tortuosity syndrome – Treatment Phenylketonuria – Basic Information Leiomyosarcoma metastatic – Treatment Alternating hemiplegia of childhood – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Clindamycin LUNSEKIMIG Jnj-77242113 Gad20-209-Fsp-A3 Venetoclax Obeticholic Acid Efavirenz Niflumic Acid Volrustomig Exidavnemab Ustekinumab Nvdx3 Cytarabine MZE829 Perflutren Bi 1291583 Tivozanib Upadacitinib Delandistrogene Moxeparvovec Apremilast More therapies…

    Learn about Your Condition

    Angelman's syndrome Myeloid leukaemia Carotid artery stenosis Haemolytic uraemic syndrome Raynaud's phenomenon Gastrooesophageal cancer Rectal cancer Vulval cancer Viral myocarditis Autism spectrum disorder Pseudoxanthoma elasticum Colorectal cancer stage IV Cancer fatigue Combined immunodeficiency Sinusitis bacterial More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Olanzapine
    • Bortezomib
    • Dexamethasone
    Greece

  • Study of Selinexor, Bortezomib, and Lenalidomide with Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    Denmark Estonia Norway

  • Study on Imaging Multiple Myeloma Patients Using Fluciclovine (18F) PET/CT

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Fluciclovine (18F)
    Norway

  • Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    • B-cell lymphoma
    • Plasma cell myeloma
    Investigated Drugs:
    • Autologous T-Cells Encoding A Chimeric Antigen Receptor Targeting Human B Cell Maturation Antigen
    • Rapcabtagene Autoleucel
    • Tisagenlecleucel
    Austria Belgium Denmark Finland France Germany +6

  • Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Iberdomide
    • Dexamethasone
    Austria Germany

  • Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Lenalidomide
    The Netherlands
Previous Page
1 … 3 4 5 6 7 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!